

# Q1FY25

## Godrej Consumer Products Ltd.



## Godrej Consumer Products Ltd.

**Stable Performance in India and Indonesia; enhanced GAUM profitability**

|                   |                     |                           |                                  |                                     |                    |
|-------------------|---------------------|---------------------------|----------------------------------|-------------------------------------|--------------------|
| CMP<br>INR 1,394* | Target<br>INR 1,541 | Potential Upside<br>10.5% | Market Cap (INR Mn)<br>14,22,743 | Recommendation<br><b>ACCUMULATE</b> | Sector<br>Consumer |
|-------------------|---------------------|---------------------------|----------------------------------|-------------------------------------|--------------------|

### Result highlights

- For Q1FY25, GCPL reported revenue of INR 33,316 Mn (-3.4% YoY, -1.6% QoQ), missed our estimates by 4.2%.
- Q1FY25 EBITDA of INR 7,262 Mn (+6.5% YoY, -4.5% QoQ), missed our estimates by 4.4%. EBITDA margin was at 21.8%, expanded by 203 bps YoY/ (-66 bps QoQ).
- Adj. PAT (excl. exceptional items) of INR 4,728 Mn (+7.6% YoY, -2.9% QoQ) exceeded our estimates by 4.0%, driven by exceptional items and lower-than-expected depreciation and tax rates.
- GCPL declared an interim dividend at INR 5.0/share for FY24-FY25.
- We slightly tweaked FY25E estimates and raised FY26E Adj. EPS by 1.2%, considering the deepening of market penetration and expansion of product basket through new launches, which is expected to drive higher volumes and profitability. **We revise the P/E multiple to 55.0x (earlier: 50x) on FY26E EPS of INR 28.0 (earlier: INR 27.7), resulting in a target price of INR 1,541/share (earlier: INR 1,426). Given a 10.5% upside potential from the CMP, we maintain our “ACCUMULATE” rating on Godrej Consumer Products Ltd.**

### MARKET DATA


|                   |            |
|-------------------|------------|
| Shares O/S (Mn)   | 1,023      |
| Mkt Cap (INR Mn)  | 14,22,743  |
| 52 Wk H/L (INR)   | 1,525/ 960 |
| Volume Avg (3m K) | 1,195      |
| Face Value (INR)  | 1          |
| Bloomberg Code    | GCPL IN    |

### KEY FINANCIALS

| Particulars (INR Mn) | FY21    | FY22    | FY23    | FY24    | FY25E   | FY26E   |
|----------------------|---------|---------|---------|---------|---------|---------|
| Revenue              | 110,286 | 122,765 | 133,160 | 140,961 | 152,846 | 170,881 |
| EBITDA               | 24,431  | 24,917  | 25,392  | 30,703  | 34,328  | 39,910  |
| PAT                  | 17,208  | 17,834  | 17,025  | -5,606  | 23,008  | 28,672  |
| Adj. PAT             | 18,201  | 18,898  | 18,653  | 20,432  | 23,229  | 28,672  |
| EPS                  | 16.8    | 17.4    | 16.7    | -5.5    | 22.5    | 28.0    |
| Adj. EPS             | 17.8    | 18.5    | 18.2    | 20.0    | 22.7    | 28.0    |
| EBITDA Margin (%)    | 22.2%   | 20.3%   | 19.1%   | 21.8%   | 22.5%   | 23.4%   |
| Adj. NPM (%)         | 16.5%   | 15.4%   | 14.0%   | 14.5%   | 15.2%   | 16.8%   |

Source: Company, KRChoksey Research

### SHARE PRICE PERFORMANCE



### Currency devaluation impacted overall revenue

- Consolidated organic revenue decreased by 1.0% YoY, with organic volume growth (UVG) at 2.0% YoY. This decline was primarily due to a 25.0% YoY drop in the GAUM market, on account of currency devaluation, pricing actions, and reduced trade inventory.
- India and Indonesia reported organic revenue growth of 6.0% YoY (9.0% reported) and 3.0% YoY (11.0% in constant currency), respectively.
- Volume growth was robust at 8.0% in India and 7.0% in Indonesia. Revenue growth lagged behind volume growth due to negative pricing in India (expected to end Q2FY25E) and currency depreciation in Indonesia.
- Management expects India's volume growth will improve in the coming quarters, driven by the launch of the new LV (Laundry Variant).
- Revenue from RCCL brands (Park Avenue and KamaSutra) was INR 1,530 Mn, Sexual Wellness is delivering ahead of expectations and continues to gain market share. However, the deodorant portfolio faced execution issues in urban GT and is expected to fall 15.0% to 20.0% short of EBITDA guidance.

### Healthy margin expansion

- Gross margin expanded by 211 bps YoY (-26 bps QoQ) to 55.9%.
- Overall EBITDA stood at INR 7,262 Mn, which grew by 6.5% YoY/-4.5% QoQ, with margins expanded by 203 bps YoY to 21.8% due to cost savings.
- India's EBITDA margin decreased by 20 bps to 24.7%, with management expecting FY25E margins to be similar to FY24.


### MARKET INFO

|        |        |
|--------|--------|
| SENSEX | 80,803 |
| NIFTY  | 24,699 |


### SHARE HOLDING PATTERN (%)

| Particulars | Jun-24 | Mar-24 | Dec-23 |
|-------------|--------|--------|--------|
| Promoters   | 63.0   | 63.2   | 63.2   |
| FIIIs       | 22.4   | 22.6   | 23.0   |
| DIIIs       | 9.3    | 9.0    | 8.4    |
| Others      | 5.3    | 5.2    | 5.4    |
| Total       | 100    | 100    | 100    |

\*Based on previous closing



Revenue CAGR between FY24 and FY26E



Adj. PAT CAGR between FY24 and FY26E

## Godrej Consumer Products Ltd.

### Conference Call Highlights

#### International Business

##### Indonesia:

- UVG (Underlined Volume Growth) achieved a 7.0% growth, building on a challenging base of 12.0%, which aligns with the management's targeted growth range of 6.0%-8.0%.
- Value growth was subdued at 3.0% because of currency devaluation in the quarter, but EBITDA saw a robust increase of 24.0% in Indian Rupees.
- In contrast to the previous year, when HIT's contribution was disproportionately high (30.0% to 35.0% revenue mix), management expects more balanced growth this year, **with Stella projected to outpace HIT.**
- In Q1FY25, **Stella/Hair Care saw double-digit volume growth**, while HIT's volumes increased in the low-single digits due to a high base. Blended UVG was affected by a decline in smaller brands, **which make up 15.0% to 20.0% of revenue.**
- HIT faces competition from Japanese and American firms in Indonesia, but recent MNC boycotts have not affected performance. **GCPL plans to raise Indonesia's margins from 20.0% to 25.0%.**

##### GAUM (Global Africa and Middle East):

- The Company had a challenging quarter, with organic volume and revenue declining by 21.0% and 25.0%, respectively. Contributing factors included: - 1) Extreme currency volatility, leading to trade destocking in Nigeria due to currency appreciation (trade typically holds 60-70 days of stock). 2) A shipping crisis affecting South Africa, though volumes have since recovered in July. 3) Difficult pricing decisions. 4) A one-time increase in distributor base in Nigeria, which inflated primary sales in the base quarter.
- Given the initially high channel inventory in Nigeria, it is uncertain whether restocking will occur if the currency depreciates.
- GCPL refined its portfolio by reducing low-margin SKUs and increasing prices. **High interest rates in many African markets (over 30.0% in Ghana) will lead GCPL to continue reducing trade stocks over the next 1-2 quarters, potentially impacting GAUM's volume growth.**
- However, this is not **expected to significantly affect offtakes or profits.** Despite the revenue decline in Q1FY25, EBITDA (incl. FX) increased by 19.0%, and the EBITDA margin remained above 14.0% for the second consecutive quarter, driven by cost reductions, effective pricing, and portfolio adjustments.
- LATAM also experienced poor topline performance but saw strong bottom-line growth. The revenue mix of GAUM/LATAM declined from 29.0% to 21.0% YoY, while the profit mix increased from 11.0% to 12.0% YoY.

##### India

- Organic UVG increased by 8.0% (reported 10.0%) compared to a 10.0% base in Q1FY24. Organic revenue growth was 6.0%, and **management expects this to be the final quarter of negative pricing growth.**
- **GCPL expects a sequential improvement in pricing, aiming for a 200-300 bps increase by the end of FY2025E.**
- Management expects to recover this loss over the year without compromising soap quality. They are optimistic that the relaunch of the GK Laundry Variant with the RNF molecule is expected to boost India volumes beyond Q1FY25 levels.
- India's EBITDA grew 8.0%, affected by a sharp rise in palm oil prices, which took 1-2 months to address through pricing adjustments. **Management expects to maintain India's EBITDA margin YoY despite palm oil inflation.** While RCCL (Raymond Consumer Care Limited) margins are improving, they will still be below the Indian average.
- GCPL is launching **Godrej Pet Care** to enter the INR 50.0 Bn pet care market, a high-margin segment with global margins of ~40.0% to 50.0% GM and ~15.0% to 25.0% EBITDA. With only 10.0% pet ownership and low packaged food penetration in India, GCPL expects substantial growth. They plan to invest INR 5.0 Bn over five years, starting manufacturing in H2FY26E. Godrej Agrovet will handle R&D and manufacturing.
- GCPL's **deodorant growth appears flat** due to revenue simplification, but underlying momentum is strong.
- The Company in the deodorant segment gained a share in modern trade, e-commerce, and rural areas but lost in urban GT. Reverting to RCCL's GT approach may delay profit targets for FY2025E.
- **Hair care** was hit by fewer weddings this quarter but will normalize soon. Godrej Expert Rich Crème leads in distribution, with strong shampoo hair color growth.
- BIS (Bureau of Indian Standards) classifies **soap** quality by total fatty matter (TFM): 76% for grade 1, 70% for grade 2, 60% for grade 3, and 40% for baby bars. Despite high inflation, GCPL has maintained the quality of its soaps.
- **HI volume** growth was in the low single digits due to severe heat waves. The new LV (Laundry Variant) with RNF (Revolutionary New Formula) molecule **launched on July 1st is expected to show results in 5-6 months.**
- GCPL is experiencing exponential growth and strong market share gains in laundry liquid and sexual wellness. Godrej Fab is scaling up nationally, Genteel has more than doubled in salience, and Cinthol bodywash is performing well. HIT matic's RNF (Revolutionary New Formula) molecule is pending approval.

##### Other

- Post-RCCL merger, GCPL integrated all channels except the OTC (over-the-counter) condom distribution. Additionally, royalty income from the divested East Africa business was negligible in Q1FY25.


## Godrej Consumer Products Ltd.

### Valuation and view


GCPL delivered a healthy Q1FY25 performance, driven by robust results in India and Indonesia, though partially offset by the GAUM segment. The Company is adeptly navigating challenges and focusing on strategic growth, particularly through its expansion into pet care. With a strong emphasis on innovation and improved distribution, GCPL is well-positioned for continued market strength and sustained profitability, enhancing shareholder value in the long term.

We slightly tweaked FY25E estimates and raised FY26E Adj. EPS by 1.2%, considering the deepening of market penetration and expansion of product basket through new launches, which is expected to drive higher volumes and profitability. We expect Revenue/EBITDA/Adjusted PAT to grow at CAGRs of 10.1%/14.0%/18.5%, respectively, over FY24-FY26E. The stock is currently trading at 61.6x/49.7x our EPS estimates for FY25E/FY26E. We revise the P/E multiple to 55.0x (earlier: 50.0x) on FY26E EPS of INR 28.0 (earlier: INR 27.7), resulting in a target price of INR 1,541/share (earlier: INR 1,426). Given a 10.5% upside potential from the CMP, we maintain our “ACCUMULATE” rating on Godrej Consumer Products Ltd.


Revenue growth impacted “GAUM” segment




EBITDA margin remained above 20.0% sequentially



Consolidated volume growth in high single digits, organic growth in low- single digits



Sequential Increase in % revenue contribution from India



Source: Company, KRChoksey Research

Source: Company, KRChoksey Research

## Godrej Consumer Products Ltd.

### KEY FINANCIALS

| Q1 FY25 Results (INR Mn)            | Q1FY25        | Q4FY24         | Q1FY24        | Q-o-Q           | Y-o-Y          |
|-------------------------------------|---------------|----------------|---------------|-----------------|----------------|
| <b>Sales</b>                        | <b>33,316</b> | <b>33,856</b>  | <b>34,489</b> | <b>-1.6%</b>    | <b>-3.4%</b>   |
| <b>Total Expenditure</b>            | <b>26,054</b> | <b>26,252</b>  | <b>27,671</b> | <b>-0.8%</b>    | <b>-5.8%</b>   |
| Cost of Raw Materials               | 12,897        | 13,042         | 16,413        | -1.1%           | -21.4%         |
| Purchase of Stock-in-trade          | 2,146         | 1,652          | 1,264         | 29.9%           | 69.8%          |
| Changes in Inventories              | -335          | 163            | -1,722        | -306.0%         | -80.5%         |
| Employee Cost                       | 2,796         | 3,237          | 3,140         | -13.6%          | -11.0%         |
| Other Expenses                      | 8,550         | 8,159          | 8,576         | 4.8%            | -0.3%          |
| <b>EBITDA</b>                       | <b>7,262</b>  | <b>7,604</b>   | <b>6,818</b>  | <b>-4.5%</b>    | <b>6.5%</b>    |
| <b>EBITDA Margins (%)</b>           | <b>21.8%</b>  | <b>22.5%</b>   | <b>19.8%</b>  | <b>-66 bps</b>  | <b>203 bps</b> |
| Depreciation                        | 495           | 499            | 763           | -0.9%           | -35.2%         |
| <b>EBIT</b>                         | <b>6,768</b>  | <b>7,105</b>   | <b>6,055</b>  | <b>-4.7%</b>    | <b>11.8%</b>   |
| Interest Expense                    | 878           | 785            | 740           | 11.8%           | 18.6%          |
| Other Income                        | 771           | 638            | 691           | 20.8%           | 11.6%          |
| <b>PBT</b>                          | <b>6,661</b>  | <b>6,958</b>   | <b>6,007</b>  | <b>-4.3%</b>    | <b>10.9%</b>   |
| Exceptional Items                   | 221           | 23,803         | 1,208         | -99.1%          | -81.7%         |
| Tax                                 | 1,933         | 2,087          | 1,611         | -7.4%           | 20.0%          |
| Share of profit of equity accounted | 0             | 0              | 0             | NA              | NA             |
| <b>PAT</b>                          | <b>4,507</b>  | <b>-18,932</b> | <b>3,188</b>  | <b>-123.8%</b>  | <b>41.4%</b>   |
| <b>PAT Margin</b>                   | <b>13.5%</b>  | <b>-55.9%</b>  | <b>9.2%</b>   | <b>6945 bps</b> | <b>428 bps</b> |
| <b>Adj. PAT</b>                     | <b>4,728</b>  | <b>4,871</b>   | <b>4,396</b>  | <b>-2.9%</b>    | <b>7.6%</b>    |
| <b>Adj. PAT Margin</b>              | <b>14.2%</b>  | <b>14.4%</b>   | <b>12.7%</b>  | <b>-20 bps</b>  | <b>145 bps</b> |
| <b>EPS</b>                          | <b>4.4</b>    | <b>-18.5</b>   | <b>3.1</b>    | <b>NA</b>       | <b>41.0%</b>   |
| <b>Adj. EPS</b>                     | <b>4.6</b>    | <b>4.8</b>     | <b>4.3</b>    | <b>-2.9%</b>    | <b>7.4%</b>    |

| Income Statement (INR Mn)             | FY22           | FY23           | FY24           | FY25E          | FY26E          |
|---------------------------------------|----------------|----------------|----------------|----------------|----------------|
| <b>Revenues</b>                       | <b>122,765</b> | <b>133,160</b> | <b>140,961</b> | <b>152,846</b> | <b>170,881</b> |
| COGS                                  | 60,751         | 67,028         | 63,203         | 67,673         | 76,656         |
| <b>Gross profit</b>                   | <b>62,014</b>  | <b>66,132</b>  | <b>77,758</b>  | <b>85,173</b>  | <b>94,225</b>  |
| Employee cost                         | 11,041         | 11,115         | 12,493         | 13,271         | 14,525         |
| Other expenses                        | 26,055         | 29,625         | 34,562         | 37,574         | 39,790         |
| <b>EBITDA</b>                         | <b>24,917</b>  | <b>25,392</b>  | <b>30,703</b>  | <b>34,328</b>  | <b>39,910</b>  |
| <b>EBITDA Margin</b>                  | <b>20.3%</b>   | <b>19.1%</b>   | <b>21.8%</b>   | <b>22.5%</b>   | <b>23.4%</b>   |
| Depreciation & amortization           | 2,099          | 2,363          | 2,410          | 2,351          | 2,223          |
| <b>EBIT</b>                           | <b>22,818</b>  | <b>23,029</b>  | <b>28,294</b>  | <b>31,977</b>  | <b>37,687</b>  |
| Interest expense                      | 1,102          | 1,757          | 2,964          | 4,080          | 3,186          |
| Other income                          | 897            | 1,685          | 2,690          | 3,433          | 3,729          |
| <b>PBT</b>                            | <b>21,553</b>  | <b>21,327</b>  | <b>1,982</b>   | <b>31,109</b>  | <b>38,230</b>  |
| Tax                                   | 3,719          | 4,303          | 7,588          | 8,101          | 9,557          |
| Exceptional items (including FX loss) | 1,064          | 1,629          | 26,037         | 221            | 0              |
| <b>PAT</b>                            | <b>17,834</b>  | <b>17,025</b>  | <b>-5,606</b>  | <b>23,008</b>  | <b>28,672</b>  |
| <b>Adj. PAT</b>                       | <b>18,898</b>  | <b>18,653</b>  | <b>20,432</b>  | <b>23,229</b>  | <b>28,672</b>  |
| <b>EPS (INR)</b>                      | <b>17.4</b>    | <b>16.7</b>    | <b>-5.5</b>    | <b>22.5</b>    | <b>28.0</b>    |
| <b>Adj. EPS</b>                       | <b>18.5</b>    | <b>18.2</b>    | <b>20.0</b>    | <b>22.7</b>    | <b>28.0</b>    |

| Cashflow Statement (INR Mn)                       | FY22    | FY23     | FY24     | FY25E    | FY26E    |
|---------------------------------------------------|---------|----------|----------|----------|----------|
| Net Cash Generated From Operations                | 14,506  | 21,507   | 20,699   | 24,858   | 28,751   |
| Net Cash Flow from/(used in) Investing Activities | (8,642) | (17,583) | (33,630) | 183      | (12)     |
| Net Cash Flow from Financing Activities           | (3,795) | (7,943)  | 14,064   | (14,800) | (16,794) |
| Net Inc/Dec in cash equivalents                   | 2,068   | (4,020)  | 1,133    | 10,242   | 11,945   |
| Opening Balance                                   | 5,241   | 7,509    | 3,576    | 4,028    | 14,269   |
| Adjustments                                       | 200     | 87       | (68)     | 0        | 0        |
| Closing Balance Cash and Cash Equivalents         | 7,509   | 3,576    | 4,028    | 14,269   | 26,214   |

Source: Company, KRChoksey Research

## Godrej Consumer Products Ltd.

| Balance Sheet (INR Mn)               | FY22           | FY23           | FY24           | FY25E          | FY26E          |
|--------------------------------------|----------------|----------------|----------------|----------------|----------------|
| <b>Non-current assets</b>            |                |                |                |                |                |
| Property, plant and equipment        | 12,749         | 14,374         | 12,813         | 12,491         | 12,238         |
| Capital work-in-progress             | 1,148          | 416            | 782            | 782            | 782            |
| Goodwill                             | 53,768         | 58,223         | 50,264         | 50,264         | 50,264         |
| Other Intangible assets              | 24,692         | 25,773         | 39,569         | 39,073         | 38,956         |
| Intangible assets under development  | 17             | 38             | 52             | 52             | 52             |
| Investments in associate             | 0              | 0              | 106            | 106            | 106            |
| Other Investments                    | 1,711          | 8,393          | 17,875         | 17,875         | 17,875         |
| Loans                                | 0              | 0              | 0              | 0              | 0              |
| Other                                | 251            | 216            | 249            | 249            | 249            |
| Deferred tax assets (net)            | 7,315          | 7,028          | 3,842          | 3,842          | 3,842          |
| Other non-current assets             | 937            | 487            | 929            | 929            | 929            |
| Right to assets                      | 985            | 967            | 1,651          | 1,651          | 1,651          |
| Non-Current Tax Assets (net)         | 896            | 1,013          | 1,216          | 1,216          | 1,216          |
| <b>Total non-current assets</b>      | <b>104,468</b> | <b>116,928</b> | <b>129,347</b> | <b>128,529</b> | <b>128,159</b> |
| <b>Current assets</b>                |                |                |                |                |                |
| Inventories                          | 21,299         | 15,372         | 12,709         | 13,608         | 15,414         |
| Investments                          | 8,443          | 21,897         | 17,162         | 18,878         | 20,766         |
| Trade receivables                    | 11,163         | 12,453         | 15,354         | 16,648         | 18,613         |
| Cash and cash equivalents            | 7,509          | 3,576          | 4,028          | 14,269         | 26,214         |
| Other Balances with Banks            | 3,569          | 331            | 1,442          | 1,442          | 1,442          |
| Loans                                | 1              | 1              | 0              | 0              | 0              |
| Other                                | 418            | 423            | 912            | 989            | 1,106          |
| Other current assets                 | 4,471          | 4,008          | 4,006          | 4,343          | 4,856          |
| <b>Total current assets</b>          | <b>56,873</b>  | <b>58,060</b>  | <b>55,612</b>  | <b>70,178</b>  | <b>88,411</b>  |
| <b>TOTAL ASSETS</b>                  | <b>161,341</b> | <b>174,988</b> | <b>184,959</b> | <b>198,707</b> | <b>216,570</b> |
| <b>EQUITY AND LIABILITIES</b>        |                |                |                |                |                |
| <b>Equity</b>                        |                |                |                |                |                |
| Equity share capital                 | 1,023          | 1,023          | 1,023          | 1,023          | 1,023          |
| Other equity                         | 114,537        | 136,920        | 124,963        | 136,467        | 150,803        |
| <b>Total equity</b>                  | <b>115,559</b> | <b>137,942</b> | <b>125,986</b> | <b>137,490</b> | <b>151,826</b> |
| <b>LIABILITIES</b>                   |                |                |                |                |                |
| <b>Non-current liabilities</b>       |                |                |                |                |                |
| Financial liabilities                |                |                |                |                |                |
| Borrowings                           | 3,809          | 1,891          | 0              | 0              | 0              |
| Other financial liabilities          | 0              | 0              | 0              | 0              | 0              |
| Provisions                           | 1,070          | 1,034          | 1,666          | 1,807          | 2,020          |
| Deferred tax liabilities (net)       | 519            | 615            | 1,038          | 1,038          | 1,038          |
| Lease liability                      | 644            | 576            | 358            | 663            | 663            |
| Other non-current liabilities        | 23             | 16             | 7              | 7              | 7              |
| <b>Total non-current liabilities</b> | <b>6,065</b>   | <b>4,132</b>   | <b>3,070</b>   | <b>3,515</b>   | <b>3,728</b>   |
| <b>Current liabilities</b>           |                |                |                |                |                |
| Borrowings                           | 12,591         | 8,829          | 31,864         | 31,864         | 31,864         |
| Trade payables                       | 21,631         | 18,232         | 16,755         | 17,940         | 20,321         |
| Other financial liabilities          | 2,272          | 2,664          | 3,440          | 3,730          | 4,170          |
| Other current liabilities            | 2,238          | 2,290          | 2,350          | 2,549          | 2,849          |
| Provisions                           | 762            | 752            | 910            | 986            | 1,103          |
| Current tax liabilities, (net)       | 222            | 147            | 585            | 634            | 709            |
| <b>Total current liabilities</b>     | <b>39,716</b>  | <b>32,913</b>  | <b>55,903</b>  | <b>57,702</b>  | <b>61,016</b>  |
| <b>Total liabilities</b>             | <b>45,781</b>  | <b>37,045</b>  | <b>58,973</b>  | <b>61,217</b>  | <b>64,744</b>  |
| <b>Key Ratio</b>                     |                |                |                |                |                |
| EBITDA Margin (%)                    | 20.3%          | 19.1%          | 21.9%          | 22.5%          | 23.4%          |
| Tax rate (%)                         | 17.3%          | 20.2%          | 27.8%          | 26.0%          | 25.0%          |
| Net Profit Margin (%)                | 14.5%          | 12.8%          | 13.1%          | 15.1%          | 16.8%          |
| RoE (%)                              | 15.4%          | 12.3%          | 12.7%          | 16.7%          | 18.9%          |
| RoCE (%)                             | 18.8%          | 16.2%          | 19.1%          | 22.7%          | 24.2%          |
| EPS (INR)                            | 18.5           | 18.2           | 20.9           | 22.7           | 28.0           |
| PE                                   | 75.4x          | 76.4x          | 69.8x          | 61.4x          | 49.8x          |

Source: Company, KRChoksey Research

## Godrej Consumer Products Ltd.

| Godrej Consumer Products Ltd. |           |         |                |
|-------------------------------|-----------|---------|----------------|
| Date                          | CMP (INR) | TP(INR) | Recommendation |
| 21-Aug-24                     | 1,394     | 1,541   | ACCUMULATE     |
| 09-May-24                     | 1,330     | 1,426   | ACCUMULATE     |
| 03-Feb-24                     | 1,237     | 1,443   | BUY            |
| 09-Nov-23                     | 1,016     | 1,204   | BUY            |
| 10-Aug-23                     | 1,028     | 1,204   | BUY            |
| 12-May-23                     | 1,008     | 1,160   | BUY            |

| Rating Legend (Expected over a 12-month period) |                |
|-------------------------------------------------|----------------|
| Our Rating                                      | Upside         |
| Buy                                             | More than 15%  |
| Accumulate                                      | 5% – 15%       |
| Hold                                            | 0 – 5%         |
| Reduce                                          | -5% – 0        |
| Sell                                            | Less than – 5% |

### ANALYST CERTIFICATION:

I, Unnati Jadhav (MMS, Finance ), Research Analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### Terms & Conditions and other disclosures:

KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSPL is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH00001295. It is also registered as a Depository Participant with CDSL, CDSL Registration No IN-DP-425-2019.

KRChoksey Shares & Securities Pvt Ltd. and DRChoksey Finserv Private Ltd. (Demerged entity from KRChoksey Shares & Securities Limited) are regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of Research Analysts including preparing and distribution of Research Reports. This research report is prepared and distributed by DRChoksey Finserv Private Ltd in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH00001246. It may be further notified that KRCSPL carries on the activity of preparation as well as distribution of reports in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH00001295.

The information and opinions in this report are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSPL. While we would endeavour to update the information herein on a reasonable basis, KRCSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension follows applicable regulations and/or KRCSPL policies, in circumstances where KRCSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on KRCSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities. KRCSPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers. KRCSPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, I, Unnati Jadhav Research Analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

KRCSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

KRCSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

KRCSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

KRCSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that, Unnati Jadhav, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

KRCSPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Please send your feedback to [research.insti@krchoksey.com](mailto:research.insti@krchoksey.com)

In case of any grievances, please write to [grievance@krchoksey.com](mailto:grievance@krchoksey.com)

Visit us at [www.krchoksey.com](http://www.krchoksey.com)

KRChoksey Shares and Securities Pvt. Ltd.

CIN-U67120MH1997PTC108958

Registered Office: 1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai – 400 001.

Phone: 91-22-6633 5000; Fax: 91-22-6633 8060

Corporate Office: 701-702, DLH Plaza, Opp Shoppers Stop, S V Road, Andheri (W), Mumbai 400 058

Phone: 91-22-66535000

Compliance Officer: Varsha Shinde

Email: [varsha.shinde@krchoksey.com](mailto:varsha.shinde@krchoksey.com)